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Abstract
Background: Uveitis, a group of disorders characterised by intraocular inflammation, causes 10–15% of total
blindness in the developed world. The most sight-threatening uveitis affects the posterior segment of the eye
(posterior-segment involving uveitis (PSIU)). Numerous different outcomes have been used in clinical trials
evaluating alternative treatments for uveitis, limiting inter-trial comparison and aggregation of data. We aim to
develop a core outcome set (COS) that would provide a standardised set of outcomes to be measured and
reported in all effectiveness trials for PSIU.
Methods: A three-phase design will be used informed by recommendations from the Core Outcome Measures in
Effectiveness Trials (COMET) initiative. Phase 1: a comprehensive list of outcomes will be identified through both a
systematic review of effectiveness trials of PSIU and qualitative research with stakeholders. The qualitative study will
comprise focus groups with patients and their carers in parallel with one-to-one telephone interviews with health
professionals and policy-makers. In the focus groups, patients will be grouped according to whether or not their
uveitis is complicated by the sight-threatening condition uveitic macular oedema (UMO) since it is hypothesised
that the presence of UMO may significantly impact on patient experience of PSIU. Phase 2: Delphi methodology
will be used to reduce the range of potential outcomes for the core set. Up to three Delphi rounds will be used
through an online survey. Participants will be asked to rate the importance of each outcome on a 9-point Likert
scale where 9 is most important. Phase 3: a consensus meeting will be held with key stakeholders to discuss the
Delphi results and ratify the final outcomes to be included in the COS.
Discussion: The development of an agreed COS for PSIU would help ensure that outcomes which matter to key
stakeholders are captured and reported in a consistent way. A COS for PSIU would allow greater comparison and
aggregation of data across trials for the better evaluation of established and emerging therapies through evidence
synthesis and meta-analysis to inform clinical guidelines and health policy.
Trial registration: COMET. http://comet-initiative.org/studies/details/640. August 2015.
Keywords: Uveitis, Core outcome set, Macular oedema, Domain, Delphi, Interviews, Focus group, Consensus method,
Clinical trials, Key stakeholders
* Correspondence: mxt500@bham.ac.uk
1Institute of Applied Health Research, College of Medical and Dental
Sciences, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK
5Centre for Patient Reported Outcome Research, Institute of Applied Health
Research, College of Medical and Dental Sciences, University of Birmingham,
Edgbaston, Birmingham B15 2TT, UK
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Tallouzi et al. Trials  (2017) 18:576 
DOI 10.1186/s13063-017-2294-8
Background
Uveitis describes a group of disorders characterised by
intraocular inflammation responsible for 10–15% of total
blindness in the developed world and up to 25% of
blindness in the developing world [1–9]. Although
uveitis may affect any age group, it peaks in the
working-age population and has a disproportionately
high impact in terms of years of potential vision loss [1]
and need for long-term therapy with its socioeconomic
impact being estimated to be at least as significant as
that of diabetic retinopathy [9].
The most sight-threatening uveitis affects the more
posterior structures of the eye, classified anatomically as
intermediate, posterior and panuveitis [10, 11]. In
clinical trials, these uveitic diseases are often grouped
together as posterior segment-involving uveitis (PSIU)
because of a number of shared features including their
higher risk of sight-threatening complications and their
requirement for systemic or local injection-based ther-
apy. One of the most important complications in uveitis
is uveitic macular oedema (UMO) which affects around
one-third of patients with PSIU [1, 12–14]. UMO is a
leading causes of sight loss in these patients and, due to
its impact on the ‘central vision’ essential for reading,
driving or recognising people’s faces, may be hypothe-
sised to have a distinct impact on patients with PSIU.
There is currently a major unmet need in the treat-
ment of PSIU with a paucity of high-level evidence to
allow evaluation and licensing of therapies by regulatory
authorities [15] and to inform treatment decisions by
clinical experts and patients [16]. One of the major
blocks identified in this area has been around ‘outcome
measures’: the inadequacy of many of the standard out-
comes used and inconsistency of the use of these out-
comes between trials [15]. A systematic search of clinical
trial registries noted that in 104 clinical trials of PSIU 14
different outcomes were used as a primary outcome, the
most common being ‘visual acuity’, ‘vitreous haze’ or
‘macular oedema’. Even where the same domain was
used there was often variation in the way it was mea-
sured, analysed and reported [17]. This has seriously
limited coherent evidence synthesis and meta-analysis in
the field.
Inconsistent use and reporting of outcome measures
can be addressed through the use of the core outcome
set (COS). The COS is a standardised set of outcomes
that have been scientifically agreed and are measured
and reported in all trials for a specific clinical area [18].
The COS is not restrictive since other data can be
collected, but rather ensures that certain key outcomes
are always collected in a standardised way. This may
profoundly enhance evidence synthesis by enabling com-
parison (due to the consistent collection of outcomes),
reducing outcome-reporting bias (as the whole COS is
reported) and improving the statistical power of any
meta-analysis (more studies can be included). Develop-
ment of the COS is supported by a number of initiatives
such as the Core Outcome Measures in Effectiveness
Trials (COMET) initiative [18] and has been endorsed
by Cochrane and the World Health Organisation [19].
The development of a COS for PSIU would provide for
the first time a standardised set of outcomes to be mea-
sured that has value to all stakeholders and can be used in
all comparative efficacy or effectiveness trials in uveitis
[20]. This has the potential to profoundly enhance evi-
dence synthesis and reduce research waste [19, 21] with
direct benefits to patients with sight-threatening uveitis.
Aims and objectives
Aims
The aim of this study is to define a COS for PSIU for use
in effectiveness trials in adult patients. In addition, we will
evaluate any difference in priorities that arise from the
presence or absence of the key sight-threatening compli-
cation, UMO.
Objectives
There are three specific objectives for the study:
1. To identify a comprehensive list of potential
outcomes based on (a) systematic review of clinical
trials in PSIU and (b) findings from key respondent
focus groups and interviews (patients, carers, health
professionals, health policy-makers).
2. To prioritise outcomes through a Delphi process,
and to evaluate any potential impact of the presence
or absence of UMO.
3. To discuss the Delphi results and finalise the COS
for PSIU through a consensus meeting with the key
stakeholder groups (patients, carers, clinicians,
policy-makers).
Methods
A three-phase approach will be used to develop a com-
prehensive COS, in which any relevant outcome identi-
fied by any stakeholder will be considered. This may
therefore include clinical parameters: patient-reported
function, quality of life and health-economic factors,
among others. First, a comprehensive list of outcomes
will be identified through a review of outcomes reported
in existing trials (systematic review) and qualitative re-
search with stakeholders. Second, a Delphi process will
be used, asking the stakeholders to prioritise outcomes
for relevance through an online survey. Third, a consen-
sus meeting will be held with key stakeholders to discuss
the Delphi results and confirm the final outcomes to be
included in the COS [22]. The study design is illustrated
in Fig. 1.
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Phase 1: identifying a comprehensive list of potential
outcomes to be included in the COS
Systematic reviews
A systematic review will be conducted on the effective-
ness of pharmacological agents for PSIU (including
PSIU with UMO) and potential outcomes will be
identified for inclusion in the COS. The identified
outcomes from the systematic review will be used to
supplement the list of outcomes identified in the
qualitative research. The combined list will be reviewed
to make sure they provide clear meaning and no
duplication [23].
Standard systematic review methodology will be
employed to identify, select and extract data from com-
parative studies (randomised/non-randomised and ob-
servational studies) of pharmacological interventions in
patients with UMO. Searches will be conducted through
bibliographic databases (Cochrane Library, MEDLINE,
EMBASE and CINAHL) and clinical trials registers. No
restriction will be placed on either language or year of
publication. Translation of non-English language articles
will be undertaken to minimise selection bias. Data
extraction will include the following: basic trial informa-
tion and name, investigator names, year of study, primary
outcome, secondary outcomes, method of measurement
and analysis for all outcomes [23].
Qualitative research
Potential outcomes to be included in the COS will be
identified through focus groups with patients and carers,
and one-to-one telephone interviews with health profes-
sionals, health policy-makers and commissioners.
Fig. 1 Flow diagram illustrating study design
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Focus groups with patients and carers
Participants Participants are patients with PSIU and
their carers. To be included as a ‘Patient Participant’, the
individual must: have a confirmed diagnosis of uveitis
involving the posterior segment of the eye (intermediate
uveitis, posterior uveitis or panuveitis) with or without
macular oedema; have active follow-up for their PSIU;
be at least 18 years of age; have the capacity to read and
write the English language as well as good spoken
English; and have the capacity to give written consent. Pa-
tient participants will be allocated to either the PSIU with
UMO group or the PSIU without UMO group based on
whether they have had UMO within the last 2 years. For
inclusion as a ‘Carer Participant’, a carer is defined as a
person at least 18 years of age (e.g. friend, family member
or spouse) who provides unpaid and informal care to the
patient during his/her illness and treatment journey for
uveitis and UMO. Carers will attend the same focus group
as the patient they are accompanying.
Patients will not be included if: they have purely
anterior uveitis; or they have other unrelated ocular co-
morbidities such as age-related macular degeneration, or
diabetic retinopathy that might have significant impact
on their vision and experience of uveitis. The presence
of uveitis complications such as glaucoma, cataract, ret-
inal vasculitis and choroidal neovascularisation are not
exclusion criteria, but will be recorded and reported;
these complications are not expected to segregate with
either the UMO or non-UMO group and therefore
should be approximately equally distributed. Nevertheless,
if it was clinically felt that any of these complications was
the main cause of vision impairment, those patients would
be excluded. Peak central macular thickness will be re-
ported for all patients in which OCT has been undertaken
as part of their clinical care. Most recent best corrected
visual acuity will be reported in all cases.
Recruitment Patients will be recruited from the NHS
Uveitis Clinics at the Birmingham and Midland Eye
Centre (Sandwell and West Birmingham Hospitals NHS
Trust) and University Hospitals Birmingham NHS
Foundation Trust. Eligible participants (patients and
their carers) meeting the inclusion criteria will be identi-
fied by ophthalmologists (PIM and AKD). A recruitment
pack will be distributed and include an invitation letter
and a participant information sheet. Written consent will
be taken on the day of the focus group. The recruitment
process and the consent pathway are illustrated in Fig. 1.
Sampling To ensure a maximum range of views and
opinions are collected [24], patients will be purposively
sampled according to the following key characteristics:
patients with uveitis with vs without UMO; patients with
currently active vs inactive disease; age; and gender. We
will aim to recruit approximately six participants per
focus group, with a total number of participants for this
stage anticipated to be between 24 and 30. Initially, four
focus groups will be conducted, two each of PSIU with
and without UMO, although further groups may be con-
vened depending on judgements of data saturation [25].
Data collection (focus groups)
Focus groups will seek to identify outcomes that are
important to patients and their carers. Whilst a variety
of approaches will be utilised in order to understand
participant perspectives, key areas for discussion will
include the experience of uveitis and the impact on pa-
tients’ and carers’ lives; their hopes and expectations for
treatment and life with uveitis; as well as discussion
about outcomes that they would prioritise. A topic guide
will be used to facilitate the focus group discussion. The
focus group discussions will be audio-recorded.
One-to-one telephone interviews with health professionals,
policy-makers and commissioners
Participants Participants will include health profes-
sionals who are involved in caring for patients with
PSIU, health policy-makers and commissioners with an
influence on uveitis care. The use of telephone inter-
views facilitates wide geographical coverage and is felt to
be more practicable for these participants [26, 27].
Recruitment Recruitment of health professionals, health
policy-makers and health commissioners will be via UK
and international clinical, research and health service
networks. Potential participants will be contacted via
email containing an invitation letter and study informa-
tion sheet, with a single reminder 2 weeks later. For
those who agree to participate, a reminder will be sent
2 days prior to the interview date.
Sampling The aim is to recruit approximately 15–20 in-
terviewees (depending on judgements of data saturation)
to include clinical, policy and commissioning perspectives.
Data collection (interviews)
One-to-one telephone interviews will be conducted to
identify outcomes that are important to clinical and policy
participants. A topic guide broadly equivalent to that used
in the patient and carer focus groups will be used as a
basis for discussion. Interviews will be audio-recorded
with oral consent obtained at the start of each interview.
Data analysis
Focus groups and interviews will be transcribed clean
verbatim for analysis. A thematic analysis of content will
be informed by the framework analytical approach [28].
Analysis will be conducted with reference to recordings,
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transcripts and field notes taken at the time of data
collection. Following initial familiarisation, data will be
coded and then indexed prior to establishing thematic
frameworks. These frameworks will enable comparative
analysis of outcomes identified between key groups, in-
cluding evaluating whether the presence of UMO affects
the outcomes identified by patients with PSIU. Data col-
lection and analysis will run concurrently.
Synthesis of comprehensive outcome list
The results of the literature review and the qualitative
study will be merged to form a single comprehensive list
of outcomes. These will be finalised through discussion
with representatives of stakeholder groups who will help
ensure standardisation and appropriate phrasing for ease
of understanding for all groups.
Phase 2: Delphi methodology
An online Delphi study will be used to reduce the range
of potential outcomes to a smaller core set [29]. A
Delphi approach informed by work of the COMET
Initiative will be used [18], including sequential rounds
through which the participants’ opinions are sought and
fed back anonymously. Additionally, participants are en-
couraged to re-evaluate their responses in the light of
these new data [30]. There will be no direct contact be-
tween participants, but participants will be asked to
participate in sequential questionnaires that constitute
different rounds [29, 31]. A recruitment pack that in-
cludes an invitation to the study alongside participant
information sheet will be sent to the eligible participants.
A key part of COS philosophy is to ensure wide stake-
holder engagement such that patients, carers, physicians
and other health staff contribute to COS development.
The Delphi technique has been and will continue to be
an important data collection methodology with a wide
variety of applications and uses for people who want to
gather information from those who are immersed and
embedded in the topic of interest and can provide real-
time and real-world knowledge [22].
Recruitment
A broader group of participants representing the key
stakeholder groups will be approached, via local and na-
tional patient groups and clinical and research networks,
and invited to participate in the survey. Additionally,
participants from the focus groups and interviews will
also be invited to take part in the Delphi study. Clini-
cians will be invited through international expert groups
while nurse practitioners will be invited via the Inter-
national Ophthalmic Nurses Associations (IONA) and
Moorefield’s Eye Hospital. Respondents will be sent a
direct link to the online survey. The purpose of the
Delphi process and participant information (e.g. voluntary
participation, confidentiality/anonymity, right to with-
draw) will be introduced at the front of the survey.
Participants will provide consent by confirming the
‘required field’ button, which states “I have read the infor-
mation provided, and agree to participate in this survey”.
Sampling
The sample size for the Delphi methodology is antici-
pated to be approximately 120 participants comprising
40 patients with PSIU (20 with UMO, 20 without
UMO), 20 carers, 40 health professionals and 20 policy-
makers. Although there is no consensus on the sample
size used in Delphi methodology, the chosen sample size
is based upon previous Delphi studies [29, 32].
Delphi rounds
A minimum of two Delphi rounds, including all of the
stakeholders’ groups, will be conducted. If consensus is
not reached, however, further rounds will be considered
until consensus is reached [22].
Delphi round one
In the first round of the Delphi process, an online survey
will be introduced for completion by the participants.
Agreement will be confirmed with those who wish to
participate and a unique ID number will be provided to
gain access to the Delphi survey. If participants are not
able to have access to the online survey, a paper copy of
the survey will be provided. If the survey is not com-
pleted within 5 working days of the initial date, a re-
minder will be sent. Participants will be asked to identify
the key stakeholder group they belong to; health profes-
sionals and health policy-makers will also be asked to
provide their professional role and years of experience.
The list of outcomes generated in Phase 1 (systematic
review and qualitative studies) will be presented to the
participants, who will be asked to rate their importance
on a 9-point Likert scale (1 = no importance; 9 = critical).
Two additional free-text boxes will be provided to respond
to the following questions: “Do you think there are any
other outcomes that should be measured in patients with
uveitis affecting the back of the eye (posterior-segment
involving uveitis)?”and “Any other comments?”.
At the end of round one, the response rate in each of
the stakeholder groups will be assessed. If the response
rate is below target, second reminders will be sent and if
necessary further recruitment will be considered. If any
additional outcomes have been identified by respondents
these will be included in round two. The Delphi process
is illustrated in Fig. 2.
Delphi round two
Participants from round one will be invited to partici-
pate in round two. Participants will be provided with the
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results from the own stakeholder group. Participants will
be asked to rate the outcomes again (including any new
outcomes identified in round one) on the 9-point scale.
Further Delphi rounds will be conducted if consensus is
not reached.
Delphi analysis
At the end of the final round, responses will be analysed
with a view to determining whether each outcome
should be included in the final COS. ‘Consensus In’ will
be based on an outcome being scored 7–9 by more than
70% participants, and being scored 1–3 by fewer than
25% participants. ‘Consensus Out’ will be based on an
outcome being scored 7–9 by more than 70% and being
scored 1–3 by less than 25%. Outcomes for which there
is no consensus will be brought for discussion to the
consensus meeting.
A pre-specified secondary analysis will also be under-
taken looking at the effect of stakeholder group and the im-
pact of the presence of UMO on the scoring of outcomes.
Phase 3: consensus meeting
The Delphi process will conclude with a face-to-face
consensus meeting of key stakeholders, the aim of which
is to achieve a consensus COS for PSIU. The results of
the Delphi study will be fed back to participants, with
greatest emphasis being placed on the results of the final
round. Discussion will focus on the following three aims:
approving all outcomes identified as ‘Consensus In’ at
the end of the final Delphi round; considering whether
further outcomes should be included when a clear ra-
tionale is provided; and to check for redundancy be-
tween outcomes. It is intended that all participants
involved in Phases 1 and 2 will be invited to attend, al-
though due to the practical constraints of a face-to-face
meeting we anticipate that this will be around 20–30
people. A priority will be to ensure that there is appro-
priate balance of representation of the different stake-
holder groups.
Discussion
Currently there is no consensus on which outcome mea-
sures should be collected in uveitis trials. This hetero-
geneity of outcome renders comparison of trials and
formal meta-analysis difficult or even impossible. All
used outcomes currently have been largely determined
by clinical experts, with minimal engagement from other
stakeholders. Many of the outcomes used are not mean-
ingful to patients, and most are not recognised as an ac-
ceptable outcome by regulatory authorities such as the
Fig. 2 Delphi procedure. Legend: The Delphi procedure for the COSUMO study. Each round comprises an on-line questionnaire resulting in a
feedback report which is presented as a supplemental file to the next round’s questionnaire. A criterion for consensus is defined in the context
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Food and Drug Administration (FDA) or the European
Medicines Agency (EMA). The development of a COS
for PSIU would for the first time provide a standardised
set of outcomes that has value to all stakeholders and
can be used in all future effectiveness trials in uveitis.
The value of a COS is increasingly recognised. Benefits
include maximising the value of each clinical trial since
key outcomes are measured and reported in all relevant
trials; ensuring that outcomes measured include those
that are most important to each group of stakeholders,
rather than just to one group; reducing outcome-
selection bias and outcome-reporting bias since the
whole COS is measured and reported; and improving
the statistical power of any meta-analysis since more
studies can be included [19, 20].
An important feature of most COS development is the
involvement of patients and other key stakeholders from
the outset, to ensure that the final COS does not simply
reflect medical perceptions of the disease but includes
those outcomes that matter to patients, and those which
are required by regulators and policy-makers to make
licensing and funding decisions. The current paradigm
for outcome assessment and reporting in uveitis is based
on the Standardisation of Uveitis Nomenclature (SUN)
workshop in 2005. This was a major step forward in the
process of standardising the methods for reporting clin-
ical data in the field of uveitis [11, 33], but was based on
the consensus of clinical experts only. Patients, carers
and health professionals may differ as to which out-
comes are most important, and there may be a tendency
for clinicians to undervalue a number of outcomes that
matter to patients [5, 34, 35]. Work in other diseases
suggests that functional outcomes seem to be more
meaningful to patients and may be under-represented
compared to clinical and anatomic outcomes that are
easier to measure [36].
Furthermore, since publication of the SUN criteria, a
number of newer instrument-based measures have be-
come available, notably optical coherence tomographic
(OCT) measurement of macular thickness to detect and
quantify macular oedema. Such measures provide ob-
jectivity and sensitivity to change that is attractive to re-
searchers and triallists but may be less meaningful to
patients. Our proposed COS methodology will address
these issues by compiling a contemporary long list of po-
tential outcomes derived from systematic review of trials
in PSIU and additional outcomes identified by patients
and other key stakeholders, which will then be priori-
tised through a Delphi approach and a consensus meet-
ing to produce the final COS [37–41].
A potential influence on the output from the Delphi is
the cut-off values for determining consensus. We have
sought to reduce bias by stipulating these a priori. These
cut-off values are estimated empirically with the purpose
of avoiding two pit-falls: first that an outcome that is
critical to one group might wrongly be excluded due to
it being scored low by one or more other groups; and
second that the criteria for consensus were too stringent
for a significant number of outcomes, leading to exces-
sive weight being placed on the consensus meeting
where personal dynamics and stakeholder power may
have disproportionate influence.
These issues also hint at the fundamental question of
whether the views of all stakeholders are equal in the
COS process, and if not, then how should this be
weighted. One of the advantages of the COS is that it is
not limited to a predetermined small number of out-
comes – there is room for the most important outcomes
from any and all key stakeholder groups, provided that
consensus can be reached.
Identification of the core outcomes for inclusion in the
COS is an important step, which will improve data syn-
thesis and allow cross-study comparison. The next phase
is to go on to identify and agree measures for consistent
assessment of these core outcomes. Candidate measures
for these outcomes will have been identified during this
project. Future work will include the assessment of the
suitability of specific measurement tools aligned to the
COS based on their measurement properties including
their construct validity, reliability and responsiveness.
Whilst acknowledging some of the challenges to COS
development, it is clear that COS has huge potential to
improve the value of clinical trials to society and to re-
duce research waste. The current approach to measuring
outcomes in uveitis is acknowledged to be inadequate.
The development of a COS for PSIU would be a major
step forward for the uveitis community as we seek to
improve the treatment of patients with the most sight-
threatening uveitis.
Trial status
At the time of manuscript submission, the status of the trial
is ongoing. Patient recruitment has not been completed.
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